Abstract:
:Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that is curable in at least 80 % of patients. Although patients usually present with painless lymphadenopathy, a variety of systemic and organ-specific syndromes may also exist in relation to HL. These syndromes may develop before, during, or after the diagnosis of HL and may also indicate disease relapse. Most of these unusual disorders resolve with successful HL treatment but some may require adjunctive supportive therapies before a response is achieved. Oncologists should be familiar with these syndromes because early recognition may result in a more timely diagnosis of HL which may lead to improved outcomes.
journal_name
Curr Hematol Malig Repjournal_title
Current hematologic malignancy reportsauthors
Barber NA,Bierman PJdoi
10.1007/s11899-012-0131-4subject
Has Abstractpub_date
2012-09-01 00:00:00pages
186-92issue
3eissn
1558-8211issn
1558-822Xjournal_volume
7pub_type
杂志文章,评审abstract::The DNA hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered disease-modifying therapies for patients with higher-risk myelodysplastic syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, and only 10-20 %...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0273-2
更新日期:2015-09-01 00:00:00
abstract::Multiple myeloma (MM) is characterized by abnormal proliferation of plasma cells in the bone marrow leading to symptoms of anemia, renal failure, hypercalcemia, and bone lesions. Bone imaging is critical for the diagnosis, staging, assessment for the presence and extent of bone lesions, and initial treatment of MM. Sk...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-017-0379-9
更新日期:2017-06-01 00:00:00
abstract::Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-010-0043-0
更新日期:2010-04-01 00:00:00
abstract:PURPOSE OF REVIEW:Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond,...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0477-3
更新日期:2018-12-01 00:00:00
abstract::Allogeneic hematopoietic cell transplantation (HCT) has curative potential for patients with myelodysplastic syndromes (MDS), though with considerable nonrelapse mortality and morbidity. The International Prognostic Scoring System, despite its confines, remains a widely used tool guiding treatment decisions in MDS. Th...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-009-0035-0
更新日期:2010-01-01 00:00:00
abstract::Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but more recent data suggest that the median OS may be longer than 5...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-009-0028-z
更新日期:2009-10-01 00:00:00
abstract:PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00593-2
更新日期:2020-08-01 00:00:00
abstract:PURPOSE OF REVIEW:Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematic...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0445-y
更新日期:2018-06-01 00:00:00
abstract::A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-013-0176-z
更新日期:2013-12-01 00:00:00
abstract::Among the few drugs that have shown a benefit for patients with acute myeloid leukemia (AML) in randomized clinical trials over the last several decades is the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO). Undoubtedly, this experience has highlighted the value of antigen-specific immunotherapy in AML. A wi...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0250-9
更新日期:2015-06-01 00:00:00
abstract::Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0283-0
更新日期:2015-12-01 00:00:00
abstract::High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown to improve survival in patients with multiple myeloma in randomized trials and is the standard of care for eligible patients. Recent randomized trials suggest a survival benefit with tandem ASCT, notably for patients failing to achi...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-007-0017-z
更新日期:2007-05-01 00:00:00
abstract::Patients with acute leukemia who undergo hematopoietic stem cell transplantation (HSCT) are susceptible to malnutrition caused by several factors including intensive cytotoxic therapy. This paper discusses the significance of malnutrition in these patients and provides an overview of nutrition therapy by the oral, ent...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-996-0007-6
更新日期:2006-09-01 00:00:00
abstract::No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients. Thera...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-009-0013-6
更新日期:2009-04-01 00:00:00
abstract::Acute promyelocytic leukemia (APL) is characterized by coagulopathy, leukopenic presentation and sensitivity to anthracyclines, all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). For the last 25 years, APL has been treated with a combination of ATRA and chemotherapy for induction followed by consolidation and ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-014-0205-6
更新日期:2014-06-01 00:00:00
abstract::Advances in chemotherapy administration have made acute lymphoblastic leukemia (ALL) a curable disease; however, most patients will relapse, despite readily attaining a complete remission. Treatment of relapse has shown dismal results with little advances made in the recent decades. Antigenic-directed therapy of ALL c...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-012-0120-7
更新日期:2012-06-01 00:00:00
abstract:PURPOSE OF REVIEW:To discuss the impact that next-generation sequencing has had on myeloproliferative neoplasm prognosis and treatment response. RECENT FINDINGS:Extended genetic testing has led to a more comprehensive understanding of the mutational landscape in the myeloproliferative neoplasms. More refined prognosti...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-019-00514-y
更新日期:2019-06-01 00:00:00
abstract::The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-012-0129-y
更新日期:2012-09-01 00:00:00
abstract::Measuring the quality of care for patients with chronic cancers is difficult, especially for heterogeneous malignancies such as the myelodysplastic syndromes (MDS). Recent work suggests that improvements may be needed in the quality of diagnostic, treatment, and end-of-life care for patients with these syndromes. More...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-016-0343-0
更新日期:2016-12-01 00:00:00
abstract::Haploidentical hematopoietic stem cell transplantation (HSCT) using mismatched family member donors has historically been complicated by high rates of nonrelapse toxicity and the need for laboratory expertise in depleting grafts of T lymphocytes. Over the past decade, improvements in supportive care, the increased use...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-007-0027-x
更新日期:2007-07-01 00:00:00
abstract:PURPOSE OF REVIEW:Antibody-drug conjugates are a new class of therapeutic agents in the treatment of B cell malignancies. In this review, we summarize the recent developments of polatuzumab vedotin in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). RECENT FIN...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00572-7
更新日期:2020-04-01 00:00:00
abstract::The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0290-1
更新日期:2015-12-01 00:00:00
abstract:PURPOSE OF REVIEW:Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with long-term use. Fedratinib, momelotinib, and pa...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00596-z
更新日期:2020-12-01 00:00:00
abstract::Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline bas...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章
doi:10.1007/s11899-014-0219-0
更新日期:2014-09-01 00:00:00
abstract::Internal tandem duplications (ITD) and tyrosine-kinase domain (TKD) mutations of the FMS-like tyrosine-kinase 3 (FLT3) can be found in up to one third of patients with acute myeloid leukemia (AML) and confer a poor prognosis. First discovered 20 years ago, these mutations were identified as viable therapeutic targets,...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-017-0381-2
更新日期:2017-06-01 00:00:00
abstract:PURPOSE OF REVIEW:Social media has dramatically changed the access and exchange of information in healthcare and beyond. A variety of platforms and resources exist allowing blood and marrow transplant providers, researchers, and patients to interact. We review the adoption of social media by the transplantation communi...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0487-1
更新日期:2018-12-01 00:00:00
abstract:PURPOSE OF REVIEW:Over the past two decades, the introduction of tyrosine kinase inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four agents currently approved for frontline use in chronic-phase (CP) disease, it follows that treatment decision-making has been rendered more challe...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0449-7
更新日期:2018-06-01 00:00:00
abstract:PURPOSE OF REVIEW:Artificial intelligence (AI), and in particular its subcategory machine learning, is finding an increasing number of applications in medicine, driven in large part by an abundance of data and powerful, accessible tools that have made AI accessible to a larger circle of investigators. RECENT FINDINGS:...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00575-4
更新日期:2020-06-01 00:00:00
abstract:PURPOSE OF REVIEW:Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications. RECENT FINDINGS:Dedicated geriatric assessment tools can aid the clini...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0454-x
更新日期:2018-06-01 00:00:00
abstract::Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not only to intrinsic characteristics such as cytogenetics and molecular markers, but also the patient's ability to tolerate therapy, and treatment response. Allogeneic stem cell transplantation (allo-HCT) has been traditionally indicat...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-014-0207-4
更新日期:2014-06-01 00:00:00